Patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV coinfected patients participating in an Italian compassionate-use program of ombitasvir/ paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) +/- ribavirin (RBV).
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients With HIV/HCV Coinfection: Results of an Italian Compassionate Use Program
Bruno Cacopardo;
2017-01-01
Abstract
Patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV coinfected patients participating in an Italian compassionate-use program of ombitasvir/ paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) +/- ribavirin (RBV).File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
OmbitasvirParitaprevirRitonavir and Dasabuvir Combination Treatment in Patients With HIVHCV Coinfection Results of an Italian Compassionate Use Program.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Dimensione
894.46 kB
Formato
Adobe PDF
|
894.46 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
